Japan-based pharmaceutical giant Takeda (TYO: 4502) has released its financial results for the 6-month period ending September 30, 2023, with global revenues hitting JPY 2.1 trillion (USD 14.0 billion). This represents a 6.4% year-on-year (YOY) increase in reported terms, or a more modest 1.4% growth at constant exchange rates (CER). The company’s performance was bolstered by its plasma-derived therapies (PDTs), gastroenterology, neuroscience, and rare diseases segments, which grew 17.2%, 3.0%, 3.2%, and 1.9% YOY respectively at CER, compensating for the 3.0% decline in oncology and a 23.1% drop in other areas.
Leading Drug Sales
Between April and September, Takeda’s drug sales were spearheaded by Entyvio (vedolizumab), an inflammatory bowel disease (IBD) medicine, which accounted for JPY 347 billion (USD 2.3 billion) in revenue. This was followed by immunoglobulin PDT at JPY 245 billion (USD 1.6 billion) and the stimulant medication Vyvanse/Elvanse (lisdexamfetamine) at JPY 211 billion (USD 1.4 billion). The remainder of Takeda’s products lagged significantly behind in terms of sales.
Geographical Revenue Breakdown
Geographically, the US market was the largest contributor, bringing in JPY 1.1 trillion (USD 7.4 billion). Europe and Canada combined for JPY 460 billion (USD 3.1 billion), while Japan contributed JPY 228 billion (USD 1.5 billion). Asia, excluding Japan, generated JPY 123 billion (USD 821 million), Latin America produced JPY 92.1 billion (USD 613 million), the Commonwealth of Independent States (CIS) added JPY 31.1 billion (USD 207 million), and other regions contributed JPY 62 billion (USD 413 million).
China Market Highlights
The report highlighted strong demand in the China market for Takecab/Vocinti (vonoprazan), a therapy for acid-related diseases, as well as for Takeda’s albumin products. This underscores the growing importance of the Chinese market for Takeda’s revenue and strategic planning.-Fineline Info & Tech
